Stocks Health care PHVS
NASDAQ · Health carePharvaris N.V. (PHVS)
It posted a net loss of $26M. Its latest periodic report to the SEC is the annual report (foreign issuer) (20-F) filed on April 2, 2026.
Key facts about Pharvaris N.V.
- Net worth
- Pharvaris N.V. has a market value (market cap) of $2.4B at the latest share price. A company's "net worth" usually means this market value or the shareholders' equity on its balance sheet.
- Latest report
- The latest periodic report (annual report (foreign issuer), 20-F) was filed with the SEC on April 2, 2026 and covers the period to December 31, 2025. Open on SEC EDGAR
What Pharvaris N.V. does
Pharvaris N.V. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker PHVS.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2020 | n/a | -$26M | n/a | n/a |
| 2020 | n/a | -$8M | n/a | n/a |
| 2018 | n/a | -$4.3M | n/a | n/a |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Pharvaris N.V. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 8, 2026
- September 8, 2026
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 12, 2026
- July 31, 2026Passive stake changed SCHEDULE 13G/A
- June 26, 2026
- June 11, 2026
- May 15, 2026Passive stake changed SCHEDULE 13G/A
- May 12, 2026
- May 11, 2026
Insider trades
What the people running Pharvaris N.V. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $20.4M worth of shares in the last 90 days and bought none on the open market. 23% of the selling was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| October 12, 2026 | Lu PengPresident | Shares withheld for tax | 117 | $3.6K |
| October 11, 2026 | Lu PengPresident | Shares withheld for tax | 109 | $3.4K |
| September 23, 2026 | Monges VivianeDirector | Exercised options | 11,969 | $96.4K |
| September 23, 2026 | Monges VivianeDirector | Sold | 11,969 | $395.5K |
| September 22, 2026 | Schikan Johannes Gerardus Christiaan PetrusDirector | Exercised options | 800 | $16K |
| September 22, 2026 | Schikan Johannes Gerardus Christiaan PetrusDirector | Sold | 800 | $29K |
| September 22, 2026 | Lu PengPresident | Exercised options | 45,308 | $117.3K |
| September 21, 2026 | Nassif David W.CFO / CLO | Sold | 6,000 | $218.8K |
Who owns PHVS
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Corey Goodman13D, may seek influence with 4 related filers | 8.4% | January 25, 2024 |
| General Atlantic, L.P.13G, passive with 14 related filers | 7.6% | August 14, 2026 |
| Viking Global Investors LP13G, passive with 6 related filers | 5.6% | May 15, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 125 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Fmr LLC | 6,565,272 | +280,800 |
| General Atlantic, L.P. | 6,550,757 | -1,480,495 |
| Foresite Capital Management IV, LLC | 4,778,581 | 0 |
| venBio Partners LLC | 4,643,430 | +4,126 |
| Viking Global Investors LP | 3,653,310 | 0 |
| EQT Fund Management S.a r.l. | 3,424,609 | 0 |
| Deerfield Management Company, L.P. | 3,376,042 | +250,000 |
| Bain Capital Life Sciences Investors, LLC | 2,675,509 | 0 |
| Wellington Management Group Llp | 2,392,934 | +274,034 |
| Polar Capital Holdings Plc | 2,326,389 | +1,545,373 |
| Point72 Asset Management, L.P. | 1,641,200 | +634,184 |
| Commodore Capital LP | 1,425,000 | -493,970 |
| Novo Holdings A/S | 1,400,000 | -350,000 |
| Saturn V Capital Management LP | 1,314,122 | +112,720 |
| TCG Crossover Management, LLC | 1,008,229 | new |
| Sofinnova Investments, Inc. | 881,299 | +62,971 |
| 5AM Venture Management, LLC | 797,600 | 0 |
| Seven Fleet Capital Management LP | 774,501 | +601,770 |
| BlackRock, Inc. | 771,454 | +14,241 |
| Cormorant Asset Management, LP | 750,000 | -250,000 |
Insiders
11 insiders reported holding 1,403,286 shares in total, about $47.6M at the last price.
| Holder | Shares |
|---|---|
| Modig BerndtChief Executive Officer, Director | 778,334650,000 held indirectly |
| Lesage AnneChief Early Development | 130,41973,969 held indirectly |
| Schikan Johannes Gerardus Christiaan PetrusDirector | 115,167 |
| Nassif David W.CFO / CLO | 113,800 |
| Lu PengPresident | 110,035 |
| Nijdam AnnaPrincipal Accounting Officer | 46,275 |
| Abele Stefan AndreasChief Technical Ops Officer | 39,068 |
| Souverijns WimChief Commercial Officer | 39,021 |
| Bjork ElisabethDirector | 15,167 |
| Glassman RobertDirector | 10,500 |
Questions about PHVS
What does Pharvaris N.V. do?
Pharvaris N.V. is a company in the Health care sector, listed on NASDAQ as PHVS. Its shares trade on NASDAQ under the ticker PHVS.
What is Pharvaris N.V.'s net worth?
Pharvaris N.V. has a market value (market cap) of $2.4B at the latest share price. A company's "net worth" usually means this market value or the shareholders' equity on its balance sheet.
Is Pharvaris N.V. profitable?
No. In fiscal 2020 it reported a net loss of $26M.
When did Pharvaris N.V. last report?
Its most recent periodic report is the annual report (foreign issuer) (20-F) filed on April 2, 2026. It covers the period to December 31, 2025. Its newest filing of any kind is the insider trade from October 13, 2026.
Similar companies
Compare PHVS with
Follow PHVS
Get an email when Pharvaris N.V. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Pharvaris N.V. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.